Skip to main content

Rare eye condition

Luxturna and retinal gene therapy

Voretigene neparvovec (Luxturna) is the first approved gene therapy for an inherited retinal disease, treating confirmed RPE65-related retinal dystrophy; many other retinal gene therapies remain in trials.

Key points

The essentials at a glance.

What to look out for, how the diagnosis is confirmed, who looks after it, and the options that exist.

  • 01

    Luxturna is available on the NHS for people with retinal dystrophy caused by confirmed variants in both copies of the RPE65 gene.

  • 02

    It is a one-time surgical injection under the retina of each eye, delivering a working copy of the gene.

  • 03

    It aims to improve or preserve remaining vision - particularly in dim light - rather than restore full sight.

  • 04

    Eligibility requires genetic confirmation and enough surviving retinal cells, assessed at a specialist inherited retinal disease centre.

  • 05

    Gene therapies for other genes, including choroideremia, X-linked RP and Stargardt disease, are in clinical trials rather than routine use.

Understanding it

What it is, and what happens next.

In plain English - what is going on, how specialists confirm it, and the routes to treatment in the UK.

Retinal gene therapy delivers a functioning copy of a faulty gene into the retinal cells using a harmless viral vector injected beneath the retina. Luxturna, for RPE65-related dystrophy, was the first to be approved and is commissioned on the NHS at designated centres; it can improve navigation in low light and slow decline, though results vary and it is not a cure.

The essential first step is genetic testing: without a confirmed RPE65 result, Luxturna is not an option, and for every other gene the honest position is that treatments are investigational. Specialist inherited retinal disease clinics keep registers of trials and can advise which programmes are recruiting for your gene. In many parts of the UK, routine NHS outpatient referrals for problems like this can take several months, whereas an initial appointment with a private consultant is typically available within around two weeks.

A quiet reminder

This guide is for information, not medical advice.

Your GP or specialist knows your history and can tell you which parts apply to you. If in doubt, speak to them.

Published 2026-09-27 · Next review 2027-09-27

Frequently asked

Common questions about Luxturna and retinal gene therapy.

Quick, plain-English answers to what people ask us most.

  • What is Luxturna gene therapy?

    Luxturna is a licensed gene therapy treatment for a specific type of inherited retinal dystrophy caused by mutations in the RPE65 gene, delivered as an injection directly into the eye to help restore some visual function. It represents one of the first approved gene therapies for an inherited eye condition.

  • Who is eligible for Luxturna gene therapy?

    Eligibility is specifically for people with confirmed biallelic RPE65 gene mutations causing inherited retinal dystrophy, and who have sufficient viable retinal cells remaining to potentially benefit from treatment. Genetic testing to confirm the specific mutation is an essential first step in determining eligibility.

  • Is Luxturna gene therapy dangerous?

    As with any injection into the eye, there are risks including infection, inflammation, or retinal complications, but it's generally considered a well-tolerated procedure when performed by an experienced specialist team. Your ophthalmologist will discuss the specific risks and expected benefits based on your individual situation.

  • How effective is Luxturna gene therapy?

    Clinical trials have shown meaningful improvement in functional vision, particularly in low-light conditions, for many appropriately selected patients, though the degree of benefit varies between individuals. Your specialist will discuss realistic expectations based on your specific retinal findings before treatment.

  • How is Luxturna gene therapy administered?

    It's given as an injection of the therapeutic gene directly beneath the retina, performed as a surgical procedure under appropriate anaesthesia by a specialist retinal surgeon. Each eye is typically treated in a separate procedure.

  • How long do the effects of Luxturna gene therapy last?

    Available long-term data suggests the benefits can be sustained for several years, though ongoing monitoring is needed to track how durable the effect remains over time as more long-term data becomes available. Your specialist will discuss what's currently known about long-term outcomes.

  • What other gene therapies are being developed for inherited retinal conditions?

    Beyond Luxturna, a number of other gene therapies for different inherited retinal conditions are in various stages of clinical trials and development, reflecting a rapidly evolving field of research. Staying in touch with a specialist genetic eye disease service helps ensure you're aware of new options as they become available.

  • Luxturna vs other treatments for inherited retinal dystrophy — what's the difference?

    Luxturna specifically targets the underlying genetic cause in a defined group of patients with RPE65 mutations, offering a potential improvement in functional vision, whereas other management for inherited retinal dystrophies more generally focuses on supportive low-vision services and monitoring, since gene therapy isn't yet available for most specific gene mutations. Genetic testing determines whether Luxturna or other emerging targeted treatments might be relevant to your specific situation.

  • Is Luxturna available on the NHS?

    It's available through specialist NHS commissioned services for eligible patients meeting specific criteria, delivered at designated specialist centres. Discussing your eligibility and referral pathway with your ophthalmologist or geneticist is the appropriate first step.

  • When should I see a specialist about Luxturna or other gene therapy options, and how quickly can I be seen privately?

    If you have a confirmed or suspected inherited retinal dystrophy, genetic testing and specialist ophthalmology assessment can clarify whether gene therapy options are relevant. Private specialist consultations can typically be arranged within about two weeks, considerably faster than some NHS specialist waiting times.